Advances in alcoholic liver disease

Current Gastroenterology Reports

Volumn 6, Issue 1, 2004, Pages 71-76

  Song, Zhenyuan ^a   Joshi Barve, Swati ^a   Barve, Shrish ^a   McClain, Craig J ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; ALPHA2 INTERFERON; CONCANAVALIN A; CYCLIC AMP; CYCLIC GMP; ENDOTOXIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6; PEGINTERFERON; PENTOXIFYLLINE; PROBIOTIC AGENT; RIBAVIRIN; S ADENOSYLMETHIONINE; SCATTER FACTOR; THYMOSIN ALPHA1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZINC; ANTIOXIDANT; CYTOKINE;

ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C; HUMAN; LIVER CELL; LIVER INJURY; LIVER TOXICITY; MOLECULAR MECHANICS; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; ANIMAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; FATTY LIVER; FEMALE; HOSPITALIZATION; IMMUNOTHERAPY; LIVER FUNCTION TEST; MALE; METABOLISM; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1442356486     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0029-y     Document Type: Review

References (47)

1. McClain CJ, Barve S, Deaciuc I, et al.: Cytokines in alcoholic liver disease. Semin Liver Dis 1999, 19:205-219.
2. Canbay A, Feldstein AE, Higuchi H, et al.: Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
3. Joshi-Barve S, Barve SS, Butt W, et al.: Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology 2003, 38:1178-1187.
4. Xu A, Wang Y, Keshaw H, et al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
5. Hill DB, Barve S, Joshi-Barve S, McClain C: Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med 2000, 135:387-395.
6. Hill DB, Marsano LS, McClain CJ: Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993, 18:576-580.
7. Hanck C, Manigold T, Bocker U, et al.: Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut 2001, 49:106-111.
8. Le Moine O, Marchant A, De Groote D, et al.: Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995, 22:1436-1439.
9. Crespo J, Cayon A, Fernandez-Gil P, et al.: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
10. Kugelmas M, Hill DB, Vivian B, et al.: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-419.
11. Woollard DJ, Grakoui A, Shoukry NH, et al.: Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. Hepatology 2003, 38:1297-1306.
12. Koop DR, Klopfenstein B, Iimuro Y, Thurman RG: Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol Pharmacol 1997, 51:944-950.
13. Iimuro Y, Gallucci RM, Luster MI, et al.: Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
14. Yin M, Wheeler MD, Kono H, et al.: Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.
15. Hill DB, D'Souza NB, Lee EY, et al.: A role for interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res 2002, 26:74-82.
16. Yang SQ, Lin HZ, Lane MD, et al.: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997, 94:2557-2562.
17. Loffreda S, Yang SQ, Lin HZ, et al.: Leptin regulates proinflammatory immune responses. FASEB J 1998, 12:57-65.
18. Li Z, Yang S, Lin H, et al.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
19. Chawla RK, Watson WH, Eastin CE, et al.: S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am J Physiol 1998, 275:G125-G129.
20. Eastin CE, McClain CJ, Lee EY, et al.: Choline deficiency augments and antibody to tumor necrosis factor-alpha attenuates endotoxin-induced hepatic injury. Alcohol Clin Exp Res 1997,21:1037-1041.
21. Tsuji H, Harada A, Mukaida N, et al.: Tumor necrosis factor receptor p55 is essential for intrahepatic granuloma formation and hepatocellular apoptosis in a murine model of bacterium-induced fulminant hepatitis. Infect Immun 1997, 65:1892-1898.
22. Tsutsui H, Matsui K, Kawada N, et al.: IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997, 159:3961-3967.
23. Nowak M, Gaines GC, Rosenberg J, et al.: LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1202-R1209.
24. Nagaki M, Tanaka M, Sugiyama A, et al.: Interleukin-10 inhibits hepatic injury and tumor necrosis factor-alpha and interferon-gamma mRNA expression induced by staphylococcal enterotoxin B or lipopolysaccharide in galactosamine-sensitized mice. J Hepatol 1999, 31:815-824.
25. Gantner F, Leist M, Lohse AW, et al.: Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995, 21:190-198.
26. Toyabe S, Seki S, Iiai T et al.: Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997, 159:1537-1542.
27. Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol 1997, 159:1418-1428.
28. Nishikage T, Seki S, Toyabe S, et al.: Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis. J Hepatol 1999, 31:18-26.
29. Bozza M, Bliss JL, Maylor R, et al.: Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. Hepatology 1999, 30:1441-1447.
30. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al.: Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
31. Lambert JC, Zhou Z, Wang L, et al.: Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. J Pharmacol Exp Ther 2003, 305:880-886.
32. Keshavarzian A, Choudhary S, Holmes EW, et al.: Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. J Pharmacol Exp Ther 2001, 299:442-448.
33. Peña LR, Hill DB, McClain CJ: Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999, 23:1-6.
34. Iimuro Y, Bradford BU, Yamashina S, et al.: The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology 2000, 31:391-398.
35. Song Z, Barve S, Chen T, et al.: S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes. Am J Physiol Gastrointest Liver Physiol 2003, 284:G949-G955.
36. Mato JM, Camara J, Fernandez de Paz J, et al.: S -adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.
37. Hasegawa T, Yoneda M, Nakamura K, et al.: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667-1672.
38. Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
39. Tilg H, Jalan R, Kaser A, et al.: Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003, 38:419-425.
40. Menon KV, Stadheim LM, Kamath PS, et al.: Analysis of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004, in press.
41. Sanderson N, Factor V, Nagy P, et al.: Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995, 92:2572-2576.
42. Ueno H, Sakamoto T, Nakamura T, et al.: A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 2000, 11:33-42.
43. George J, Roulot D, Koteliansky VE, Bissell DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719-12724.
44. Blindenbacher A, Wang X, Langer L et al.: Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003, 38:674-682.
45. Sun Z, Klein AS, Radaeva S, et al.: In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003, 125:202-215.
46. Louis H, Van Laethem JL, Wu W et al.: Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998, 28:1607-615.
47. Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al.: Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int Immunopharmacol 2003, 3:1169-1176.